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Abstract
Background: Tumor necrosis factor-α (TNFα) is a mediator of insulin resistance. Plasma levels
of soluble TNFα receptors (sTNFR1 and sTNFR2) probably reflect paracrine action of the
cytokine. TNFα is also a regulator of lipid metabolism, however, data about impact of obesity on
the relationships between TNFα and plasma lipids remain controversial.
Aim: The purpose of the present study was to examine the associations of TNFα system with
plasma lipids in lean and obese subjects with normal glucose metabolism.
Methods: We examined 63 subjects, 33 lean (BMI<25 kg × m-2) and 30 with marked overweight
or obesity (BMI>27.8 kg × m-2). Anthropometric and biochemical parameters were measured. Oral
glucose tolerance test and euglycemic hyperinsulinemic clamp were also performed.
Results: Obese subjects were markedly more insulin resistant and had higher levels of both TNFα
receptors. Total (TC) and LDL-cholesterol (LDL-C), triglycerides (TG) and non-esterified fatty
acids (NEFA) were also higher in the obese group. In obese subjects, both receptors were
significantly related to TG and HDL-cholesterol (HDL-C), while sTNFR2 was also associated with
NEFA. All those correlations disappeared after controlling for insulin sensitivity. In lean subjects,
both receptors were related to TC, HDL-C and LDL-C. In that group, sTNFR1 predicted values
of all those parameters independently of BMI, plasma glucose and insulin, and insulin sensitivity.
Conclusion: We conclude that TNFα receptors are associated with plasma lipids in different way
in lean and in obese subjects. TNFα system is probably important in determining cholesterol levels
in lean subjects, while in obese this effect might be masked by other metabolic abnormalities.
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Background
Tumor necrosis factor-α (TNFα) is a cytokine involved in
regulation of the whole-body carbohydrate and lipid
metabolism. One of the main metabolic effects of TNFα
action is the development of insulin resistance [1]. In
insulin resistant states, the cytokine acts mostly in an
auto- and paracrine manner in adipose tissue [2] and skel-
etal muscle [3]. Two cell surface TNFα receptors were
described in humans, TNFR1 (p60) and TNFR2 (p80),
soluble forms of those receptors (sTNFR1 and sTNFR2)
are present in plasma and it is supposed that their concen-
trations, especially sTNFR2, might reflect local action of
TNFα in tissues [4]. Soluble TNFR might neutralize TNFα
at high levels, but they also might stabilize its bioactivity,
help sequester TNFα to its membrane receptors and thus
increase the effects of the cytokine [5]. Adipose tissue
TNFR2 mRNA and protein and plasma levels of sTNFR2
are increased in obesity and related to insulin resistance
[4,6], in those studies no differences in TNFR1 levels were
observed. In contrast, other authors reported an increase
in adipose tissue expression [7] and plasma levels [8] of
both receptors in obese subjects. Plasma TNFα values are
usually low and do not give the precise information about
its auto- and paracrine action. It is propose that sTNFR2
might serve as the best predictor of local TNFα system
activity [4].
There are data that TNFα might also be an important fac-
tor determining plasma cholesterol levels. The cytokine
induces an increase in serum cholesterol and in hepatic
hydro-3-methyl-glutaryl coenzyme A reductase activity in
mice [9]. TNFα also induces maturation of sterol regula-
tory element binding protein-1 (SREBP-1), an important
transcription factor in cholesterol biosynthesis [10]. There
is an evidence that TNFR2 gene polymorphism is associ-
ated with hypercholesterolemia [11] and coronary artery
disease [12]. However, data about plasma TNFα receptors
as determinants of total and LDL-cholesterol levels and
about impact of obesity on the relationships between
TNFα system and plasma lipids remain controversial
[13,14].
The aim of the present study was to examine the associa-




A total of 63 subjects, 33 lean (BMI<25 kg × m-2, 14 men
and 19 women) and 30 with marked overweight or obes-
ity (BMI>27.8 kg × m-2, 12 men and 18 women) were
recruited for the present study. The subjects were recruited
actively from Outpatient Clinic of Department of Endo-
crinology, Diabetology and Internal Medicine of Medical
University of Białystok. The basal characteristics of the
studied groups are presented in Table 1. All the subjects
were non-smokers, without ischaemic heart disease,
hypertension, peripheral vascular disease, infections or
any other serious medical problems. Only subjects with-
out family history of type 2 diabetes were recruited for the
present study. Before participating in the study, physical
examination and resting electrocardiography were per-
formed. All subjects underwent an oral glucose tolerance
test (OGTT) and all had normal glucose tolerance accord-
ing to WHO criteria. All subjects gave written informed
consent before entering the study. The study protocol was
approved by the Ethics Committee of Medical Academy,
Białystok.
Anthropometry
All analyses were performed after an overnight fast. The
BMI was calculated as body weight × height -2 (kg/m2).
The waist-to hip ratio (WHR) was also estimated. The
waist circumference was measured at the smallest circum-
ference between the rib cage and the iliac crest, with the
subject in the standing position. The hip circumference
was measured at the widest circumference between the
waist and the thighs. Percent of body fat was estimated by
bioelectric impedance analysis using the Tanita TBF-511
Body Fat Analyzer (Tanita Corp., Tokyo, Japan), fat mass
(FM) and fat-free mass (FFM) were calculated.
Insulin sensitivity
Insulin sensitivity was evaluated by the euglycemic hyper-
insulinemic clamp technique according to DeFronzo et al
[15], as described previously [16,17]. On the morning of
the study, two venous catheters were inserted into antecu-
bital veins, one for the infusion of insulin and glucose and
the other in the contralateral hand for blood sampling,
that hand was heated to approximately 60°C. Insulin
(Actrapid HM, Novo Nordisk, Copenhagen, Denmark)
was given as a primed-continuous intravenous infusion
for 2 hours at 40 mU × m-2 × min-1, resulting in constant
hyperinsulinemia of approximately 550 pmol/l. Arterial-
ized blood glucose was obtained every 5 minutes and
20% dextrose (1.11 mol/l) infusion was adjusted to main-
tain plasma glucose levels at 5.0 mmol/l. The glucose
Table 1: Anthropometric parameters in the studied groups 
(mean ± SD).
Lean subjects (n = 33) Obese subjects (n = 30)
Age (year) 35.24 ± 7.56 37.07 ± 9.68
BMI (kg × m-2) 22.23 ± 2.14 32.21 ± 3.99*
WHR 0.80 ± 0.06 0.88 ± 0.08*
Percent of body fat 17.00 ± 5.16 36.48 ± 9.36*
BMI, body mass index; WHR, waist-to-hip ratio.
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infusion rate approached stable values during final 40
minutes of the study and the rate of whole-body glucose
uptake (M value) was calculated as the mean glucose infu-
sion rate from 80 to 120 min, corrected for glucose space
and normalized per kilogram of fat-free mass (M/FFM).
Other analyses
Fasting blood samples were also taken from the antecu-
bital vein for the determination of glycated hemoglobin
(HbA1c), plasma lipids, TNFα, sTNFR1 and sTNFR2. For
the determination of plasma TNF system samples were
frozen at -70°C.
Analytical procedures
Plasma glucose was measured immediately by the enzy-
matic method using glucose analyzer (YSI 2300 STAT
Plus, Yellow Spring Instuments, OH). Plasma insulin was
measured with the Medgenix Enzyme Amplified Sensitiv-
ity Immunosorbent Assay (EASIA) test (BioSource
Europe, Nivelles, Belgium). The minimum detectable
concentration was 1.05 pg/l and the intra-assay and inter-
assay coefficients of variation (CVs) were below 5.5% and
10%, respectively. In that method, human and animal
proinsulins present no cross-reaction. HbA1c were meas-
ured by the high-performance liquid chromatography
method (Bio-Rad, Muenchen, Germany). Plasma total
(TC) and HDL-cholesterol (HDL-C) and triglycerides
(TG) were assessed by the enzymatic methods (Cormay,
Warsaw, Poland). Plasma LDL-cholesterol (LDL-C) was
calculated from the Friedewald's formula. Plasma non-
esterified fatty acids (NEFA) were measured by colorimet-
ric method [18].
Plasma TNFα concentrations were measured by the
Immunoassay Kit (BioSource International, Camarillo,
CA, USA) with the minimum detectable concentration 1.7
pg/ml and with the intra-assay and inter-assay CVs below
5.2% and 8.5%, respectively. Plasma sTNFR1 and sTNFR2
were determined with the EASIA kits (BioSource Europe).
The minimum detectable concentration was 0.05 ng/ml
for sTNFR1 and 0.1 ng/ml for sTNFR2. The intra-assay and
inter-assay CVs for both receptors were below 6.5% and
9%, respectively. sTNFR1 EASIA does not cross react with
sTNFR2 and TNFα does not interfere with the assay.
Statistical analysis
The statistics were performed with the STATISTICA 5.0
program (StatSoft, Krakow, Poland). Differences between
the groups were evaluated with an unpaired Student's t-
test. Relationships between variables were estimated with
Pearson correlation coefficient analysis and with multiple
regression analysis. Variables, which did not have normal
distribution (insulin, TG) were log-transformed before
analyses. The level of significance was accepted at p value
less than 0.05.
Results
Biochemical parameters of the studied groups are pre-
sented in Table 2. Obese subjects had higher levels of
HbA1c, plasma glucose (both p < 0.001) and insulin (p <
0.005). The obese group was also markedly more insulin
resistant (p < 0.005) and had higher levels of sTNFR1 (p <
0.0005) and sTNFR2 (p < 0.02). Plasma TNFα did not dif-
fer between the studied groups.
Plasma TC, LDL-C (both p < 0.0001), TG (p < 0.005) and
NEFA (p < 0.00005) were also higher in the obese group.
No difference in HDL-C levels was observed between the
studied groups. When we analysed all the studied popula-
tion, we observed significant correlations of both sTNFR1
Table 2: Biochemical parameters in the studied groups (mean ± SD).
Lean subjects (n = 33) Obese subjects (n = 30)
HbA1c (%) 5.34 ± 0.41 5.78 ± 0.50*
Plasma glucose (mmol/l) 4.86 ± 0.48 5.35 ± 0.57*
Plasma insulin (pmol/l) 65.84 ± 32.14 105.33 ± 68.60*
M/FFM (µmol × kg-1 × min-1) 50.50 ± 14.64 39.37 ± 12.44*
Plasma TC (mmol/l) 4.43 ± 0.78 5.52 ± 1.08*
Plasma TG (mmol/l) 1.02 ± 0.52 1.64 ± 0.93*
Plasma HDL-C (mmol/l) 1.37 ± 0.32 1.23 ± 0.41
Plasma LDL-C (mmol/l) 2.59 ± 0.81 3.52 ± 0.96*
Plasma NEFA (mmol/l) 0.347 ± 0.116 0.504 ± 0.155*
Plasma TNFα (pg/ml) 4.89 ± 1.53 5.22 ± 2.69
Plasma sTNFR1 (ng/ml) 1.94 ± 0.37 2.36 ± 0.44*
Plasma sTNFR2 (ng/ml) 4.12 ± 0.79 4.74 ± 1.20*
HbA1c, glycated hemoglobin; M/FFM, whole-body glucose uptake normalized per kg of fat-free mass; TC, total cholesterol; TG, triglycerides; HDL-
C, HDL-cholesterol; LDL-C, LDL-cholesterol; NEFA, non-esterified fatty acids; TNFα, tumor necrosis factor α; sTNFR1, soluble TNFα receptor 1; 
sTNFR2, soluble TNFα receptor 2.
*p < 0.05 in obese vs lean subjects.Cardiovascular Diabetology 2006, 5:14 http://www.cardiab.com/content/5/1/14
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and sTNFR2 with TC (r = 0.38, p < 0.005 and r = 0.31, p <
0.02), TG (r = 0.49, p < 0.0005 and r = 0.42, p < 0.001),
HDL-C (r = -0.49, p < 0.0005 and r = -0.39, p < 0.005),
LDL-C (r = 0.41, p < 0.001 and r = 0.32, p < 0.02) and
NEFA (r = 0.48, p < 0.0005 and r = 0.40, p < 0.001, respec-
tively). The correlations between TNFα system and
plasma lipids were different among groups when lean and
obese subjects were analysed separately.
In obese subjects, both receptors were significantly related
to TG and HDL-C (Fig. 1), while sTNFR2 was also associ-
ated with NEFA (r = 0.43, p < 0.05). All those correlations
disappeared after controlling for insulin sensitivity.
In lean subjects, both receptors were related to TC, HDL-
C and LDL-C (Fig. 2). All the relationships were stronger
for sTNFR1 than for sTNFR2. The correlations with TG
and NEFA did not reach the level of significance. Multiple
regression analysis revealed that sTNFR1, but not sTNFR2,
predicted plasma levels of TC (R2 = 0.24, p < 0.005), HDL-
C (R2 = 0.23, p < 0.005) and LDL-C (R2 = 0.33, p < 0.0005)
independently of BMI, plasma glucose, insulin, and insu-
lin sensitivity.
Discussion
We demonstrated an increase in both sTNFR1 and
sTNFR2 in the obese group. This is in agreement with our
previous results [19], although in a smaller study we were
able to detect an increase only in sTNFR2 [20]. The
present study shows that soluble forms of TNFα receptors
are related to plasma lipids in different way in lean and in
obese subjects.
In the obese, both receptors were associated positively
with TG and negatively with HDL-C, thus contributing to
lipoprotein profile typical for the insulin resistance syn-
drome. The relationships between TNFα receptors and
plasma lipids in the obese group disappeared after con-
trolling for insulin sensitivity, suggesting that lipid abnor-
malities associated with TNFα system in obesity might be
fully explained by TNFα-associated insulin resistance. In
contrast, in the lean group sTNFR1 and sTNFR2 were
related to TC, HDL-C and LDL-C, relationships of sTNFR1
were independent of insulin sensitivity and other exam-
ined parameters.
The present study does not show any cause-effect relation-
ships. It was reported that accumulation of cholesteryl
esters in macrophages exposed to LDL-immune com-
plexes is related to increase in TNFα synthesis and release
[21]. Hypercholesterolemic rabbits [22] and LDL-receptor
knockout mice [23] present increased TNFα secretion.
However, in a situation when an increase in TNFα or its
receptors might be secondary to hypercholesterolemia,
Relationships between soluble TNFα receptors and plasma lipids in obese subjects Figure 1
Relationships between soluble TNFα receptors and plasma lipids in obese subjects. Relationships of: A. sTNFR1 and TG, B. 












































































DCardiovascular Diabetology 2006, 5:14 http://www.cardiab.com/content/5/1/14
Page 5 of 7
(page number not for citation purposes)
one may expect a significant relationships between TNFα
system and cholesterol rather in the obese group, present-
ing higher lipid levels and higher risk of accelerated
atherogenesis. Therefore, it seems unlikely that the above
reports might help explaining findings of the present
study. It is more probable that soluble TNFRs might reflect
TNFα influence on cholesterol metabolism. The possible
mechanism might be associated with an increase in
hepatic hydro-3-methyl-glutaryl coenzyme A reductase
activity [9] and/or maturation of SREBP-1 [10].
In recent studies, a microsatellite marker with 5 alleles in
intron 4 of TNFR2 gene was reported [24]. This locus was
associated with familial combined hyperlipidemia [24],
hypertension, hypercholesterolemia [11] and coronary
artery disease [12]. The genotypic effect on plasma
sTNFR2 levels was also found [11,12]. It is suggested, that
the effects of TNFα on lipid metabolism are influenced by
TNFR2 genotype [11]. No data about TNFR1 gene poly-
morphism and lipid abnormalities are available.
Data about plasma TNFα receptors as determinants of
total and LDL-cholesterol levels and about impact of
obesity on the relationships between TNFα system and
plasma lipids remain controversial. Both sTNFR1 and
sTNFR2 were related to TC, TG and LDL-C in myotonic
dystrophy patients [25]. It was also observed that both
receptors were independent determinants of TC and LDL-
C in healthy subjects, when lean and obese subjects were
analysed together [13]. Plasma sTNFR2, but not sTNFR1,
was associated with HDL2-cholesterol. In a large study
conducted on 268 men in a wide range of BMI, both
sTNFRs were related to TC and HDL-C [14]. In that study,
however, TNFα receptors were not independent predic-
Relationships between soluble TNFα receptors and plasma lipids in lean subjects Figure 2
Relationships between soluble TNFα receptors and plasma lipids in lean subjects. Relationships of : A. sTNFR1 and TC, B. 
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tors of plasma lipids and, in contrast to insulin, did not
significantly change an association between BMI and car-
diovascular risk factors [14].
Our data show, that TNFα is especially important in deter-
mining plasma total cholesterol and its fractions in lean
subjects. This effect is probably independent of insulin
sensitivity. We observed that lean normoglycemic insulin-
resistant offspring of type 2 diabetic subjects had higher
plasma levels of sTNFR2 [26], and these levels are associ-
ated with lower plasma adiponectin in that group [27].
When we analysed offspring and control group together,
we observed similar correlations to those reported here.
To exclude the effect of diabetes-prone genotype, only
subjects with no family history of type 2 diabetes were
recruited for the present study. Our findings provide fur-
ther evidence that TNFα system might be involved in the
pathogenesis of metabolic syndrome even before the
onset of obesity and indicate that its metabolic actions
may extend beyond inducing insulin resistance.
In obese subjects probably there are other factors, genetic
or environmental (for instance nutrition), associated with
the accumulation of body fat, that are more important in
determining TC and its fractions than TNFα itself. It is
likely that those factors could mask the TNFα effect on
cholesterol metabolism. Insulin resistance, which is asso-
ciated with TNFα overactivity in obesity, might also influ-
ence lipid metabolism. Alternatively, TNFα may induce
accelerated atherogenesis in obesity by other mecha-
nisms. We demonstrated that plasma sTNFR2 increase in
parallel with soluble intercellular adhesion molecule-1
(sICAM-1) [28] and interleukin 8 [29] in obese subjects.
In the study of Elkind et al [30], both receptors predicted
maximal carotid plaque thickness independently of LDL-
C and other parameters, like BMI, diabetes or hyperten-
sion.
Conclusion
W e  c o n c l u d e  t h a t  T N F α receptors are associated with
plasma lipids in different way in lean and in obese sub-
jects. TNFα system is probably important in determining
cholesterol levels in lean subjects, while in obese this
effect might be mediated by other metabolic abnormali-
ties.
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